Human papillomavirus tumor antigen vaccine (Vanderbilt University/Ingram Cancer Center)

N/A

Report date: 2024/07/04 13:47:40

Base Information

Drug NameHuman papillomavirus tumor antigen vaccine (Vanderbilt University/Ingram Cancer Center)
Drug Alias NameTA-HPV Vaccine(Vanderbilt University/Ingram Cancer Center)
ClassificationVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsOropharyngeal NeoplasmsMouth Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVanderbilt UniversityVanderbilt-Ingram Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesVanderbilt-Ingram Cancer CenterVanderbilt University
Inactive CompaniesN/A
Active IndicationsOropharyngeal NeoplasmsMouth Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A